The incidence of venous thromboembolism in chronic myeloid leukemia treatment based on the normalized million people file of National Health Insurance Research Database of Taiwan

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 2016 第十屆嘉南藥理大學藥理學院師生研究成果發表會 > Item 310902800/31315

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31315

標題:	The incidence of venous thromboembolism in chronic myeloid leukemia treatment based on the normalized million people file of National Health Insurance Research Database of Taiwan
作者:	CHIH-WEI SU TZ-CHYANG TANG
貢獻者:	Department of Pharmacy, Chia Nan University of Pharmacy and Science
日期:	2016-05-10
上傳時間:	2018-05-21 10:34:29 (UTC+8)
摘要:	Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem cells and amongst the most common hematological malignancies encountered in adults. Nowadays, many clinical trials data show the availability of the first and second-generation Tyrosine Kinase Inhibitor (TKI) (imatinib, nilotinib, and dasatinib) in the first and second line settings. Venous thromboembolism (VTE) is a life-threatening condition that occurs as a complication of CML. This study analyzed the data of the National Health Insurance Research Database (NHIRD) deposited from 2004 to 2013, which provided by the National Health Research Institutes in Taiwan. The major outcome reveals the relationship between disease treatment and severe adverse events, especially in VTE. 9506 appendectomy patients were eligible and 90 CML patients were routed out which received TKI drugs treatment. The 10-year cumulative risk for VTE was not significant in the CML group than in the control group (4.69% vs. 2.82%, P-value 0.1239). The rate of VTE among CML patients whom received TKI drugs was not significant, too. (2.22% vs. 2.82%, P-value 0.3502) 192 CML patients were diagnosed and 90 patients had received Tyrosine Kinase Inhibitor (TKI) drug for the treatment, while 9 patients encountered vein thromboembolism event. Only two patients have VTE event during Imatinib treat. This study was limited in which the population cannot cover all of CML patients. And we cannot link to the real clinical profile to analyze the adherence and clinical effect of patients. Following the analyzed results, the patients of elder or with more complication ones maybe have higher risk than normal population in VTE, and the incidence rate of VTE is not significant vs. control group. The incidence of VTE in CML patients should not associated with TKI drugs.
關聯:	2016 第十屆嘉南藥理大學藥理學院師生研究成果發表會，起迄日：2016/05/10-2016/05/13，地點：嘉南藥理大學國際會議中心一樓
显示于类别:	[藥學系(所)] 會議論文 [藥理學院] 2016 第十屆嘉南藥理大學藥理學院師生研究成果發表會

文件中的档案:

档案	描述	大小	格式	浏览次数
A15.pdf		468Kb	Adobe PDF	590	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....